TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8997678

Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg 1 hour presurgery and 400 mg postsurgery)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 1310584

Group type: EXPERIMENTAL
Intervention: Levodopa/Carbidopa
Number of subjects: 7
Study: 6403962

Group type: EXPERIMENTAL
Intervention: Pentobarbital 200 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Pentobarbital 400 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Pentobarbital 600 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 30264977

Group type: EXPERIMENTAL
Intervention: DHEA (100 mg/day for 4 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29543133

Group type: EXPERIMENTAL
Intervention: Acute Aerobic Exercise (AE) - 40 min of cycling at ∼70% maximal HR
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acute Resistance Exercise (RE) - 8 sets, 10 reps at ∼65% 1-repetition maximum (1RM)
Number of subjects: 6
Study: 27707836

Group type: EXPERIMENTAL
Intervention: 10-week resistance training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 60
Study: 24621109

Group type: EXPERIMENTAL
Intervention: BDP/FF 200/12 μg twice daily
Number of subjects: 419

Group type: COMPARATOR
Intervention: FP/S 500/50 μg twice daily
Number of subjects: 419
Study: 21933347

Group type: EXPERIMENTAL
Intervention: Bayesian approach for lithium drug monitoring
Number of subjects: 97

Group type: COMPARATOR
Intervention: Traditional steady-state blood sampling
Number of subjects: 97
Study: 19357404

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice a day
Number of subjects: 412

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study: 18080349

Group type: EXPERIMENTAL
Intervention: Acidform
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: BufferGel
Number of subjects: 81

Group type: COMPARATOR
Intervention: KY Jelly
Number of subjects: 81
Study: 15191772

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 3044

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 3044

Group type: EXPERIMENTAL
Intervention: Haemoglobin as a continuous variable
Number of subjects: 3044

Group type: EXPERIMENTAL
Intervention: Haemoglobin sub-divided by 1.0 g/dL increments
Number of subjects: 3044

Group type: EXPERIMENTAL
Intervention: Anaemic and polycythaemic patients
Number of subjects: 3044
Study: 11589263

Group type: EXPERIMENTAL
Intervention: Ketoprofen lysine salt (KLS) mouthwash (10 mL diluted in 100 mL of water, gargled twice daily for up to 7 days)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Benzydamine hydrochloride (BH) mouthwash (15 mL, 22.5 mg, gargled twice daily for up to 7 days)
Number of subjects: 241
Study: 9647140

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 30
Study: 7801606

Group type: EXPERIMENTAL
Intervention: Constant agitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manual mixing once every 24 h
Number of subjects: 0

Group type: COMPARATOR
Intervention: No agitation
Number of subjects: 0
Study: 2686744

Group type: EXPERIMENTAL
Intervention: Cefixime 100 mg once daily (6 months to 5 years), 200 mg once daily (5 to 10 years), 300 mg once daily (10 to 16 years)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Amoxycillin 62.5 mg tds (6 months to 1 year), 125 mg tds (1 to 7 years), 250 mg tds (7 to 16 years)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 325

Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 325
Study: 810295

Group type: EXPERIMENTAL
Intervention: Propranolol (P)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30572072

Group type: EXPERIMENTAL
Intervention: Exception from informed consent (EFIC) implementation strategies including community consultation (CC) and public disclosure (PD) methods.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community consultation (CC) methods such as social media advertising, random digit dialing surveys, working with city officials, and websites with embedded surveys.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Public Disclosure activities including press releases, website documentation, and letters to community members and local officials.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time from community consultation (CC) to study approval.
Number of subjects: 0
Study: 28433995

Group type: EXPERIMENTAL
Intervention: Prophylactic dialysis (3 times prior to surgery)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no dialysis)
Number of subjects: 88
Study: 25480462

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Escitalopram and Nortriptyline
Number of subjects: 60
Study: 24341820

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) guided antibiotic therapy
Number of subjects: 225

Group type: COMPARATOR
Intervention: Standard treatment with antibiotics at physician's discretion (Control)
Number of subjects: 225
Study: 21488594

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with fluorouracil and folinic acid (de Gramont protocol)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Addition of oxaliplatin to fluorouracil + folinic acid (Folfox 4 protocol)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Addition of irinotecan to fluorouracil + folinic acid
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Fluorouracil precursors (capecitabine and tegafur)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Raltitrexed
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for stage II disease
Number of subjects: 3000
Study: 19733054

Group type: EXPERIMENTAL
Intervention: Partner present during neuraxial anesthesia placement
Number of subjects: 315

Group type: COMPARATOR
Intervention: Partner not present during neuraxial anesthesia placement
Number of subjects: 315

Group type: COMPARATOR
Intervention: Partner not present
Number of subjects: 315
Study: 17978999

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: HINT1 TT genotype
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: ARRB2 and OPRM1 genotype interaction
Number of subjects: 374
Study: 15156311

Group type: EXPERIMENTAL
Intervention: Acemetacin (ACE) 90 mg bid for 6 weeks
Number of subjects: 105

Group type: COMPARATOR
Intervention: Celecoxib (CEL) 200 mg bid for 6 weeks
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Acemetacin (ACE)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Celecoxib (CEL)
Number of subjects: 105
Study: 11410698

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) over the abdomen and posterior back muscles in addition to physical therapy for 6 weeks
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group receiving only physical therapy for 6 weeks
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) group
Number of subjects: 2
Study: 9579280

Group type: EXPERIMENTAL
Intervention: Oral tacrine treatment
Number of subjects: 16
Study: 8053616

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (3 million units) three times a week subcutaneously for 4 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (1 mL saline)
Number of subjects: 15
Study: 2789364

Group type: EXPERIMENTAL
Intervention: Ponsinomycin 800 mg syrup administered during a standard meal
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ponsinomycin 800 mg syrup administered 2 hours before a standard meal
Number of subjects: 12
Study: 31394945

Group type: EXPERIMENTAL
Intervention: Rational Emotive Behavior Therapy (REBT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 31724346

Group type: EXPERIMENTAL
Intervention: Tongdu Tiaoshen acupuncture method
Number of subjects: 96

Group type: COMPARATOR
Intervention: Non-penetrating sham acupuncture
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Health guidance (waiting group)
Number of subjects: 96
Study: 28426106

Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg/day
Number of subjects: 226

Group type: COMPARATOR
Intervention: Gefitinib 250 mg/day
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Afatinib (exon 19 deletion)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Gefitinib (exon 19 deletion)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Afatinib (L858R)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Gefitinib (L858R)
Number of subjects: 226
Study: 25654365

Group type: EXPERIMENTAL
Intervention: Low-grade IVH (grades I-II)
Number of subjects: 462

Group type: COMPARATOR
Intervention: No low-grade IVH (grades I-II)
Number of subjects: 462
Study: 22404535

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI) therapy
Number of subjects: 21
Study: 21814211

Group type: EXPERIMENTAL
Intervention: Imidapril 10 mg (titrated to 20 mg for nonresponders)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg (titrated to 32 mg for nonresponders)
Number of subjects: 84
Study: 18157638

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination in CD patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: Hepatitis B vaccination in control subjects
Number of subjects: 25
Study: 16488084

Group type: EXPERIMENTAL
Intervention: Olanzapine, 5-20 mg/day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Current therapy (pre-study antipsychotic medication)
Number of subjects: 54
Study: 12730468

Group type: EXPERIMENTAL
Intervention: Dietary assessment protocols
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meta-analysis
Number of subjects: 0
Study: 11867964

Group type: EXPERIMENTAL
Intervention: Prednicarbate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Betamethasone 17‐valerate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 9456097

Group type: EXPERIMENTAL
Intervention: Full-dose aprotinin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 8587947

Group type: EXPERIMENTAL
Intervention: Sucrose drink (160 kcals/40 grams of cane sugar)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saccharin or water (control)
Number of subjects: 0
Study: 2751592

Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 324835

Group type: EXPERIMENTAL
Intervention: Chlorpropamide (100 mg. O.D.)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Tolbutamide (500 mg. b.i.d.)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Phenformin (50 mg. O.D.)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Acetohexamide (250 mg. O.D.)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo (diet alone)
Number of subjects: 5
Study: 31758941

Group type: EXPERIMENTAL
Intervention: Preoperative regional blocks using 0.25% bupivacaine hydrochloride
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (standard anesthetic and postoperative protocols)
Number of subjects: 110
Study: 31021304

Group type: EXPERIMENTAL
Intervention: Child and parent received the prevention interventions
Number of subjects: 487

Group type: COMPARATOR
Intervention: Only the parent received the prevention intervention
Number of subjects: 487

Group type: COMPARATOR
Intervention: Neither child nor parent received the prevention interventions
Number of subjects: 487
Study: 28426834

Group type: EXPERIMENTAL
Intervention: Immediate access to PrEP
Number of subjects: 544

Group type: COMPARATOR
Intervention: Deferred access to PrEP
Number of subjects: 544
Study: 26458896

Group type: EXPERIMENTAL
Intervention: SPARX‐R, an online, gamified intervention based on cognitive behavioural principles
Number of subjects: 1600

Group type: COMPARATOR
Intervention: lifeSTYLE, an attention‐controlled placebo comparator
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: SPARX‐R
Number of subjects: 1600

Group type: COMPARATOR
Intervention: lifeSTYLE
Number of subjects: 1600
Study: 23530305

Group type: EXPERIMENTAL
Intervention: Living Well By Faith intervention (8-week program, classes held twice a week including educational workshops and exercise sessions)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (minimal intervention consisting of one educational workshop)
Number of subjects: 106
Study: 22078345

Group type: EXPERIMENTAL
Intervention: L-ornithine-L-aspartate (LOLA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 19211452

Group type: EXPERIMENTAL
Intervention: Aspirin (81 to 325 mg/d)
Number of subjects: 2967

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2967

Group type: EXPERIMENTAL
Intervention: Aspirin (any dose)
Number of subjects: 2967
Study: 16492440

Group type: EXPERIMENTAL
Intervention: Fortified maternal milk thickened by 1.5 g of precooked starch per 100 mL of milk (milk B)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Fortified maternal milk (milk A)
Number of subjects: 5
Study: 14687309

Group type: EXPERIMENTAL
Intervention: CVT‐E002 (200 mg, oral, twice daily)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 10930901

Group type: EXPERIMENTAL
Intervention: OMC 4 (4 days b.d. 20 mg omeprazole, 400 mg metronidazole, 250 mg clarithromycin followed by 6 days b.d. 20 mg omeprazole and placebo antibiotics)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: OMC 7 (7 days b.d. 20 mg omeprazole, 400 mg metronidazole, 250 mg clarithromycin followed by 3 days b.d. 20 mg omeprazole and placebo antibiotics)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: OMC 10 (10 days b.d. 20 mg omeprazole, 400 mg metronidazole, 250 mg clarithromycin)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: All three treatments (OMC 4, OMC 7, OMC 10)
Number of subjects: 76
Study: 9298124

Group type: EXPERIMENTAL
Intervention: Increased number of mast cells in non-involved skin
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Increased number of CD3+ lymphocytes in non-involved skin
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Correlation between mast cells in non-involved skin and duodenal intraepithelial lymphocytes
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Inverse correlation between CD3+ lymphocytes in non-involved skin and duodenal mast cells
Number of subjects: 43
Study: 8409033

Group type: EXPERIMENTAL
Intervention: Intervention communities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control communities
Number of subjects: 0
Study: 30715261

Group type: EXPERIMENTAL
Intervention: (Peg)IFN therapy
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: G3BP2 G-allele
Number of subjects: 1058
Study: 29946007

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 1061

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1061
Study: 27188919

Group type: EXPERIMENTAL
Intervention: Liquid contrast agent
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Semisolid contrast agent
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Liquid contrast agent in patients with severe hiatal hernia
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Liquid contrast agent in patients with mild hiatal hernia
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Liquid contrast agent in patients with no hiatal hernia
Number of subjects: 66
Study: 23656176

Group type: EXPERIMENTAL
Intervention: Intravenous patient-controlled analgesia
Number of subjects: 140

Group type: COMPARATOR
Intervention: Intravenous injection
Number of subjects: 140
Study: 22534523

Group type: EXPERIMENTAL
Intervention: Carotid extra-medial thickness
Number of subjects: 389
Study: 20307215

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) - 1-3 injections of 1.25 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Intravitreal triamcinolone acetonide (IVT) - 1-3 injections of 2 mg
Number of subjects: 31
Study: 18562489

Group type: EXPERIMENTAL
Intervention: GH therapy administered subcutaneously at 0.05 mg/kg per day until growth velocity was 1 cm/6 months
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: GH therapy in children with a mutation in PTPN11
Number of subjects: 29
Study: 16331547

Group type: EXPERIMENTAL
Intervention: Functional Mandibular Advancer (FMA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 16
Study: 12356962

Group type: EXPERIMENTAL
Intervention: Intracerebral fetal tissue grafting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 0
Study: 10340734

Group type: EXPERIMENTAL
Intervention: Flammazine
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Flammacerium
Number of subjects: 74

Group type: COMPARATOR
Intervention: Deflamol
Number of subjects: 74

Group type: COMPARATOR
Intervention: Polyvidone-iodine
Number of subjects: 74
Study: 8738857

Group type: EXPERIMENTAL
Intervention: Cholestyramine (4 g twice daily) concurrent with valproic acid (250 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cholestyramine (4 g twice daily) staggered with valproic acid (250 mg, 3 hours apart)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Valproic acid alone (250 mg)
Number of subjects: 6
Study: 1860196

Group type: EXPERIMENTAL
Intervention: recombinant tissue‐type plasminogen activator (rt‐PA)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: rt‐PA plus heparin
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: streptokinase
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: streptokinase plus heparin
Number of subjects: 180

Group type: COMPARATOR
Intervention: heparin (when begun 12 hours after intravenous thrombolysis)
Number of subjects: 180

Group type: COMPARATOR
Intervention: all treatment groups
Number of subjects: 180
Study: 6137165

Group type: EXPERIMENTAL
Intervention: Flunisolide nasal spray
Number of subjects: 45

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate nasal spray
Number of subjects: 45
Study: 29471477

Group type: EXPERIMENTAL
Intervention: MapMyFitness application and Facebook-delivered health education intervention
Number of subjects: 10
Study: 28431551

Group type: EXPERIMENTAL
Intervention: Guided Internet-based cognitive behavioural therapy (iCBT) intervention
Number of subjects: 92

Group type: COMPARATOR
Intervention: Face-to-face clinical care for tinnitus
Number of subjects: 92
Study: 26763501

Group type: EXPERIMENTAL
Intervention: Behavior Therapy (BT)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Cognitive interventions (CT and CBT)
Number of subjects: 188
Study: 24339310

Group type: EXPERIMENTAL
Intervention: Anxiety condition
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Spring (n=25)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Summer (n=21)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Seasonal differences
Number of subjects: 46
Study: 22111350

Group type: EXPERIMENTAL
Intervention: Pentazocine 0.3 mg x kg(‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pentazocine 0.6 mg x kg(‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 30
Study: 19400884

Group type: EXPERIMENTAL
Intervention: 2 days of convalescence
Number of subjects: 0

Group type: COMPARATOR
Intervention: 7 days of convalescence
Number of subjects: 0
Study: 18004133

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 30
Study: 15305553

Group type: EXPERIMENTAL
Intervention: Age group 1 (5 to 10 years)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Age group 2 (11 to 20 years)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Age group 3 (21 to 30 years)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Age group 4 (31 to 40 years)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Age group 5 (41 to 50 years)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Age group 6 (51 years or older)
Number of subjects: 120

Group type: COMPARATOR
Intervention: All age groups
Number of subjects: 120
Study: 11374522

Group type: EXPERIMENTAL
Intervention: Surgical decompression with fusion
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 81

Group type: COMPARATOR
Intervention: Neck collar
Number of subjects: 81
Study: 9543266

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training with 30% maximal inspiratory pressure (PI,max)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training with 10% maximal inspiratory pressure (PI,max)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training with 30% maximal inspiratory pressure (PI,max) and evaluated breathing pattern
Number of subjects: 31
Study: 8311488

Group type: EXPERIMENTAL
Intervention: KW-2307 single administration at 10 mg/m2 escalated to 35 mg/m2
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: KW-2307 repeated administration at 30 mg/m2 for 4 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: KW-2307 (both administration types)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: KW-2307 single administration
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: KW-2307 repeated administration
Number of subjects: 40
Study: 3289791

Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 29746337

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 1044

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 1044
Study: 26555475

Group type: EXPERIMENTAL
Intervention: Air filtration units
Number of subjects: 56

Group type: COMPARATOR
Intervention: Wood stove changeout
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo filter intervention
Number of subjects: 56
Study: 25363835

Group type: EXPERIMENTAL
Intervention: AQW051, administered over a broad dose range (up to 200 mg single dose, 75 mg multiple daily doses)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: AQW051
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180